Caplin Steriles gets USFDA nod for Labetalol Hydrochloride Injection
Labetalol Hydrochloride Injection USP is indicated for control of blood pressure in severe hypertension.
Chennai: Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited, has been granted final approval by the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Labetalol Hydrochloride Injection USP, 100 mg/20 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL) Multiple-dose Vials.
The product is a generic therapeutic equivalent version of (RLD), TRANDATE Injection, of Sebela Ireland Limited.
Labetalol Hydrochloride Injection USP is indicated for control of blood pressure in severe hypertension.
According to IQVIA (IMS Health), Labetalol hydrochloride Injection had US sales data of approximately $6 million for the 12-month period ending June 2021.
Read also: Caplin Steriles Sumatriptan injection gets USFDA okay for treating migraine, cluster headache
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd